PM Stock Recent News
PM LATEST HEADLINES
Philip Morris is entering the US market, poised to capture significant market share in smoke-free products, challenging Altria and British American Tobacco. PM's strong focus on smoke-free products, with 38% of revenue from SFPs, positions it as a leader in the industry's future. Despite lower dividends compared to competitors, PM's total return and growth potential make it a compelling investment.
PM sells Vectura Group to Molex Asia Holdings amid criticism of its ownership as it seeks to shift from tobacco to healthcare.
Philip Morris is poised for success, bolstered by its robust momentum, commitment to innovative smoke-free solutions and ability to drive profitability.
PM sells Vectura Group to Molex Asia Holdings amid criticism of its ownership as it seeks to shift from tobacco to healthcare.
Marlboro maker Philip Morris International's unit Vectura Fertin Pharma said on Tuesday it would sell its subsidiary Vectura Group to Molex Asia Holdings for 150 million pounds ($198.09 million).
STAMFORD, CT--(BUSINESS WIRE)--Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PMI) (NYSE: PM), today announces the sale of its subsidiary Vectura Group Ltd. (Vectura) to Molex Asia Holdings Ltd., and the establishment of master service agreements to develop Vectura Fertin Pharma's inhaled therapeutics proprietary pipeline. Vectura will be operated by Phillips Medisize, a Molex company. The sale includes upfront cash consideration of GBP 150 million, subject to cu.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Does Philip Morris (PM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Philip Morris is benefiting from its shift toward smoke-free products. This, along with pricing power, is aiding PM amid currency headwinds.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.